Lantheus Secures FDA Approval for BRAVNETSA, Expanding Treatment Options for GEP-NETs
Lantheus Holdings, Inc., a leader in the radiopharmaceutical sector, has announced the U.S. Food and Drug Administration (FDA) has granted final approval for BRAVNETSA™ (lutetium Lu 177 dotatate). This new approval marks BRAVNETSA as the only radiopharmaceutical deemed bioequivalent and therapeutically equivalent to LUTATHERA® for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
BRAVNETSA's approval, achieved via the FDA’s Abbreviated New Drug Application (ANDA) pathway, facilitates its use in treating adult patients with somatostatin receptor-positive GEP-NETs, expanding the arsenal of radioligand therapies available to clinicians. Lantheus' commitment to innovation is exemplified through this milestone, as BRAVNETSA becomes the first radioligand therapy approved under the ANDA process, providing a new regulatory pathway for similar future developments.
Mary Anne Heino, Executive Chairperson and CEO of Lantheus, noted, “As the only radiopharmaceutical that has been confirmed by the FDA to match the bioequivalency and therapeutic efficacy of LUTATHERA in the U.S., BRAVNETSA is a crucial addition. It underscores our commitment to broadening our radiopharmaceutical portfolio, thereby increasing treatment options for individuals coping with GEP-NETs.”
Neuroendocrine tumors, particularly GEP-NETs, represent a complex clinical challenge due to their rarity and often slow growth, which can lead to diagnostic delays. These tumors impact the gastrointestinal system and pancreas and are known for their functional and non-functional hormone activities. GEP-NETs have seen a significant rise in incidence, with U.S. estimates indicating prevalence around 200,000 patients.
Lutger Dinkelborg, PhD, Head of Research and Development at Lantheus, commented on the significance of the approval: “This pivotal approval represents a leap forward not only for our company but also for the field of radiopharmaceuticals. By leveraging our expertise to navigate the ANDA process, we provide clinicians with another FDA-sanctioned treatment choice, enabling more personalized therapeutic decisions.”
The regulatory green light for BRAVNETSA follows existing clinical guidelines and offers a new treatment avenue, addressing unmet needs within the patient community dealing with GEP-NETs. The availability of this treatment is a significant step in delivering care tailored to the molecular characteristics of neuroendocrine malignancies.
BRAVNETSA's approval underlines a thorough understanding of its implications in medical practice, emphasizing the need for healthcare professionals to adhere to precise radiation safety practices. The treatment’s potential risks and adverse effects, such as cumulative radiation exposure and myelosuppression, necessitate vigilant monitoring throughout its administration and follow-up, consistent with best practice guidelines.